BioTuesdays

Tag - NLTX

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.